Nxera Pharma
June 18, 2025
Company Presentation
Multiple Therapeutics
153B
Nxera Pharma is a technology powered biopharma company in pursuit of new specialty medicines to improve the lives of patients with unmet needs in Japan and globally. We have built an agile, new-generation commercial business in Japan to develop and commercialize innovative medicines, including several launched products, to address this high value, large and growing market and those in the broader APAC region.
Behind that, and powered by our unique NxWave™ discovery platform, we are advancing an extensive pipeline of over 30 active programs from discovery through to late clinical stage internally and in partnership with leading pharma and biotech companies. This pipeline of potentially first- and best-in-class candidates is focused on addressing major unmet needs in some of the fastest-growing areas of medicine across neurology/neuropsychiatry, metabolic diseases and immunology and inflammation.
Nxera is listed on the Tokyo Stock Exchange (ticker: 4565).
Company HQ City:
Tokyo
Company HQ State:
Tokyo
Company HQ Country:
Japan
Year Founded:
1990
Lead Product in Development:
PIVLAZ
CEO
Chris Cargill
Development Phase of Lead Product
Multiple Products in Market
Exchange
TSE
Ticker
4565
When you expect your next catalyst update?
N/A
What is your next catalyst (value inflection) update?
N/A
Website
www.nxera.life
Primary Speaker
)
)
)
)
){kind=logo}
){kind=logo}
)
){kind=logo}
)
){kind=logo}
){kind=logo}